MedPath

Bepotastine Besilate Ophthalmic Solution 1.5%

These highlights do not include all the information needed to use BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% safely and effectively. See full prescribing information for BEPOTASTINE BESILATE OPHTHALMIC SOLUTION. BEPOTASTINE Besilate Ophthalmic Solution 1.5% for topical ophthalmic use Initial U.S. Approval: 2009

Approved
Approval ID

de111d74-c740-47b3-adc7-4b855df2c561

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 21, 2023

Manufacturers
FDA

Alembic Pharmaceuticals Limited

DUNS: 650574663

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Bepotastine Besilate Ophthalmic Solution 1.5%

PRODUCT DETAILS

NDC Product Code46708-598
Application NumberANDA214588
Marketing CategoryC73584
Route of AdministrationOPHTHALMIC
Effective DateJuly 21, 2023
Generic NameBepotastine Besilate Ophthalmic Solution 1.5%

INGREDIENTS (6)

BEPOTASTINE BESILATEActive
Quantity: 15 mg in 1 mL
Code: 6W18MO1QR3
Classification: ACTIB
BENZALKONIUM CHLORIDEInactive
Code: F5UM2KM3W7
Classification: IACT
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATEInactive
Code: 5QWK665956
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Bepotastine Besilate Ophthalmic Solution 1.5% - FDA Drug Approval Details